Mitsuhiro Imasawa1,2, Toyoaki Tsumura3, Arata Sekine3, Toyohiko Kikuchi3, Hiroyuki Iijima3. 1. Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan. mimasawa@yamanashi.ac.jp. 2. Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. mimasawa@yamanashi.ac.jp. 3. Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Abstract
PURPOSE: To investigate whether the baseline mean deviation (MD) of Humphrey perimetry has a predictive value for visual improvement after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). METHODS: We retrospectively reviewed the records of 40 eyes of 39 PCV patients (28 men, 11 women) who underwent PDT. The follow-up period ranged from 12 to 42 months. Best-corrected visual acuity (BCVA) improved more than 0.2 logarithm of the minimum angle of resolution (logMAR) units at the final examination in 22 (55%) of the 40 eyes, which were classified into the "Improved group." The other 18 eyes with improvement of <or=0.2 logMAR units were classified into the "Not Improved group." RESULTS: The baseline MD in the Improved group was significantly better than that in the Not Improved group (P=0.0144). Multivariate analysis confirmed that only the baseline MD was associated with improvement of the final BCVA, showing that eyes with better baseline MD tended to exhibit improvement of the final BCVA after PDT for PCV (odds ratio=1.303; 95% confidence interval, 1.069-1.588). CONCLUSIONS: The baseline MD in Humphrey perimetry can be useful for predicting visual improvement after PDT for PCV.
PURPOSE: To investigate whether the baseline mean deviation (MD) of Humphrey perimetry has a predictive value for visual improvement after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). METHODS: We retrospectively reviewed the records of 40 eyes of 39 PCV patients (28 men, 11 women) who underwent PDT. The follow-up period ranged from 12 to 42 months. Best-corrected visual acuity (BCVA) improved more than 0.2 logarithm of the minimum angle of resolution (logMAR) units at the final examination in 22 (55%) of the 40 eyes, which were classified into the "Improved group." The other 18 eyes with improvement of <or=0.2 logMAR units were classified into the "Not Improved group." RESULTS: The baseline MD in the Improved group was significantly better than that in the Not Improved group (P=0.0144). Multivariate analysis confirmed that only the baseline MD was associated with improvement of the final BCVA, showing that eyes with better baseline MD tended to exhibit improvement of the final BCVA after PDT for PCV (odds ratio=1.303; 95% confidence interval, 1.069-1.588). CONCLUSIONS: The baseline MD in Humphrey perimetry can be useful for predicting visual improvement after PDT for PCV.
Authors: Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili Journal: Am J Ophthalmol Date: 2003-09 Impact factor: 5.258
Authors: Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong Journal: Ophthalmology Date: 2004-08 Impact factor: 12.079